The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
The Emerging Role of B Cells in the Pathogenesis of NAFLD
Hepatology. 2021 May 7. doi: 10.1002/hep.31889. Online ahead of print.
Fanta Barrow1, Saad Khan2, Haiguang Wang1, Xavier S Revelo13
Author information
1Department of Integrative Biology & Physiology, University of Minnesota, United States.
2Department of Immunology, University of Toronto, Canada.
3Center for Immunology, University of Minnesota, United States.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of abnormal liver function worldwide. NAFLD refers to a group of liver conditions ranging from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), which involves inflammation, hepatocellular damage, and fibrosis. Triggering of inflammation in NASH is a key event in the progression of the disease and identifying the factors that initiate or dysregulate this process is needed to develop strategies for its prevention or treatment. B cells have been implicated in several autoimmune and inflammatory diseases. However, their role in the pathogenesis of NAFLD and NASH is less clear. This review discusses the emerging evidence implicating intrahepatic B cells in the progression of NAFLD. We highlight the potential mechanisms of B cell activation during NAFLD such as the increased hepatic expression of the B-cell activating factor (BAFF), augmented oxidative stress, and translocation of gut-derived microbial products. We discuss the possible effector functions by which B cells promote NAFLD including the production of pro-inflammatory cytokines and regulation of intrahepatic T cells and macrophages. Finally, we highlight the role of regulatory and IgA+ B cells in the pathogenesis of NASH-associated hepatocarcinoma (HCC). In this review, we make the case that future research is needed to investigate the potential of B cell-targeting strategies for the treatment of NAFLD.